Patent ID: 11932677
Assignee: ALIVEGEN INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 3:
4. A method of treating cardiovascular disease in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of an isolated protein comprising a hybrid soluble activin IIB receptor-extracellular domain (ActRIIB-ECD) polypeptide, wherein said hybrid soluble ActRIIB-ECD polypeptide comprises the amino acid sequence selected from the group consisting of SEQ ID NO: 16 and SEQ ID NO: 29, wherein said hybrid soluble ActRIIB-ECD polypeptide is fused to an Fc domain of a human immunoglobulin via a peptide linker, and wherein the cardiovascular disease is selected from the group consisting of: muscle wasting associated with chronic heart failure, cardiac atrophy, and myocardial infarction (MI).